Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Depreciation: 2020-2024

Historic Accumulated Depreciation for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $14.6 million.

  • SAB Biotherapeutics' Accumulated Depreciation rose 21.46% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 21.46%. This contributed to the annual value of $14.6 million for FY2024, which is 47.04% up from last year.
  • SAB Biotherapeutics' Accumulated Depreciation amounted to $14.6 million in FY2024, which was up 47.04% from $9.9 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Accumulated Depreciation ranged from a high of $14.6 million in FY2024 and a low of $1.8 million during FY2020.
  • For the 3-year period, SAB Biotherapeutics' Accumulated Depreciation averaged around $10.3 million, with its median value being $9.9 million (2023).
  • Data for SAB Biotherapeutics' Accumulated Depreciation shows a peak YoY spiked of 94.98% (in 2022) over the last 5 years.
  • Over the past 5 years, SAB Biotherapeutics' Accumulated Depreciation (Yearly) stood at $1.8 million in 2020, then skyrocketed by 82.21% to $3.2 million in 2021, then skyrocketed by 94.98% to $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then spiked by 47.04% to $14.6 million in 2024.